Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors TORONTO and BOSTON, June 27, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has commenced dosing patients in the third cohort of its ongoing Phase 1b/2a clinical trial of COTI-2 plus cisplatin in solid tumors. The objective of the third cohort is to continue to evaluate the ...
Cotinga Pharmaceuticals Announces Initiation of Next Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors Independent Dose Escalation Committee (DEC) recommends continuing the study at an increased dose TORONTO and BOSTON, June 05, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has initiated the third cohort of its ongoing Phase 1b/2a clinical trial of COTI-2 plus cisplatin in...
Cotinga Pharmacueticals Announces Closing of Second Tranche of Unit Offering TORONTO and BOSTON, June 04, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that effective June 4, 2019 (the “Closing Date”), it completed, for gross proceeds of $100,000, a second tranche offering (the “Offering”) of units (“Units”) comprised of $100,000 of senior secured debentures (the “Debentures”) and 1,000,000 non-transfer...
Cotinga Pharmacueticals Announces Closing of Unit Offering TORONTO and BOSTON, May 22, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that effective May 22, 2019 (the “Closing Date”), it completed, for gross proceeds of $199,970, an offering (the “Offering”) of units (“Units”) comprised of $199,970 of senior secured debentures (the “Debentures”) and 1,999,700 non-transferable common share purchase warrant...
Cotinga Pharmaceuticals Announces Management and Board Changes LONDON, Ontario and BOSTON, July 02, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced the appointment of Victor Hugo as Chief Financial Officer (CFO), effective July 20, 2018, and the appointment of J. Matthew Bond as a member of the Board of Directors and Chairman of the Audit Committee, effective July 1, 2018. Mr. Hugo will succeed G...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.